AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39073580 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 76
Study 39073580 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 76
Study 39073712 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab
Number of subjects: 42
Study 39073712 — intervention group
Group type: COMPARATOR
Intervention: guselkumab and mirikizumab
Number of subjects: 42
Study 39073712 — intervention group
Group type: EXPERIMENTAL
Intervention: age
Number of subjects: 42
Study 39073712 — intervention group
Group type: EXPERIMENTAL
Intervention: disease duration
Number of subjects: 42
Study 39073712 — intervention group
Group type: EXPERIMENTAL
Intervention: high-risk group (risk value > 1.5)
Number of subjects: 42
Study 39073796 — intervention group
Group type: EXPERIMENTAL
Intervention: Consult for Addiction Treatment and Care in Hospitals (CATCH) program
Number of subjects: 2315
Study 39073796 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 2315
Study 39073799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg intravenous every 3 weeks for up to nine treatment cycles
Number of subjects: 0
Study 39073799 — intervention group
Group type: COMPARATOR
Intervention: Baseline scores (before treatment)
Number of subjects: 0
Study 39073812 — intervention group
Group type: EXPERIMENTAL
Intervention: iPCIT (internet-based parent-child interaction training)
Number of subjects: 71
Study 39073812 — intervention group
Group type: COMPARATOR
Intervention: Referrals as usual (control)
Number of subjects: 71
Study 39073822 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged, bilateral focused ultrasound thalamotomy
Number of subjects: 51
Study 39073823 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services.
Number of subjects: 19113
Study 39073823 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services among Black individuals.
Number of subjects: 19113
Study 39073823 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services among White individuals.
Number of subjects: 19113
Study 39073834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) via colonoscopy
Number of subjects: 45
Study 39073834 — intervention group
Group type: COMPARATOR
Intervention: Placebo via colonoscopy
Number of subjects: 45
Study 39074277 — intervention group
Group type: EXPERIMENTAL
Intervention: Free phone mount to facilitate hands-free use
Number of subjects: 1653
Study 39074277 — intervention group
Group type: COMPARATOR
Intervention: Education about the risks of handheld phone use
Number of subjects: 1653
Study 39074277 — intervention group
Group type: EXPERIMENTAL
Intervention: Other arms received education about risks and additional interventions (not specified in the abstract)
Number of subjects: 1653
Study 39074480 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 253
Study 39074480 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 253
Study 39074504 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured informational pamphlet on CRC screening and printed guide for FIT kit usage
Number of subjects: 37
Study 39074504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 37
Study 39074931 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg) and Etoposide (50 mg)
Number of subjects: 29
Study 39074964 — intervention group
Group type: EXPERIMENTAL
Intervention: preHEART score
Number of subjects: 823
Study 39074964 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 823
Study 39074964 — intervention group
Group type: COMPARATOR
Intervention: T-MACS
Number of subjects: 823
Study 39074964 — intervention group
Group type: COMPARATOR
Intervention: POC-troponin measurement alone
Number of subjects: 823
Study 39074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing with results disclosure and genetic counselling
Number of subjects: 10510
Study 39074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for GBA1
Number of subjects: 10510
Study 39074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for LRRK2
Number of subjects: 10510
Study 39074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for PRKN
Number of subjects: 10510
Study 39074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for SNCA
Number of subjects: 10510
Study 39074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for PINK1, PARK7, or VPS35 combined
Number of subjects: 10510
Study 39074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for multiple genes
Number of subjects: 10510
Study 39075139 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of inflammation composite score (Q4)
Number of subjects: 10044
Study 39075156 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 104
Study 39075156 — intervention group
Group type: COMPARATOR
Intervention: Sham manual therapy (control)
Number of subjects: 104
Study 39075268 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM (Patient Aligned Care Team Intensive Management)
Number of subjects: 456
Study 39075268 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM
Number of subjects: 456
Study 39075268 — intervention group
Group type: COMPARATOR
Intervention: Control (not referred to PIM)
Number of subjects: 456
Study 39075274 — intervention group
Group type: EXPERIMENTAL
Intervention: Difamilast 0.3% ointment applied twice daily
Number of subjects: 41
Study 39075274 — intervention group
Group type: EXPERIMENTAL
Intervention: Difamilast 0.3% or 1% ointment applied based on existing symptoms
Number of subjects: 41
Study 39075354 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 301
Study 39075354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 301
Study 39075354 — intervention group
Group type: COMPARATOR
Intervention: Control (no vasopressor administration)
Number of subjects: 301
Study 39075369 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed AKI
Number of subjects: 0
Study 39075369 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not develop AKI
Number of subjects: 0
Study 39075369 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients transferred from the Medical Floor who developed AKI
Number of subjects: 0
Study 39075454 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 0
Study 39075454 — intervention group
Group type: COMPARATOR
Intervention: Sham-taVNS
Number of subjects: 0
Study 39075465 — intervention group
Group type: EXPERIMENTAL
Intervention: YSLQQ intervention group (n=526)
Number of subjects: 1180
Study 39075465 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=654)
Number of subjects: 1180
Study 39075484 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin cessation
Number of subjects: 6103
Study 39075484 — intervention group
Group type: COMPARATOR
Intervention: Aspirin continuation
Number of subjects: 6103
Study 39075506 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare worker HTN and CVD care training plus long-term practice facilitation, electronic health record (EHR) documentation of key indicators and use of reminders, and use of treatment partners to provide social support.
Number of subjects: 4652
Study 39075506 — intervention group
Group type: EXPERIMENTAL
Intervention: InterCARE model (if successful)
Number of subjects: 4652
Study 39075531 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-radiotherapy (Doc-RT)
Number of subjects: 224
Study 39075531 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-radiotherapy (Cis-RT)
Number of subjects: 224
Study 39075535 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDS (BIDI)
Number of subjects: 25
Study 39075543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation during altitude exposure
Number of subjects: 36
Study 39075543 — intervention group
Group type: COMPARATOR
Intervention: Ambient air supplementation during altitude exposure
Number of subjects: 36
Study 39075587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus vitamin C
Number of subjects: 100
Study 39075587 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 100
Study 39075590 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer (TTT) strategy
Number of subjects: 24
Study 39075590 — intervention group
Group type: COMPARATOR
Intervention: Expert consultation condition
Number of subjects: 24
Study 39075617 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) eating pattern with supportive positive affect and mindful eating skills
Number of subjects: 17
Study 39075620 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 945
Study 39075620 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 945
Study 39075620 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 945
Study 39075620 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 945
Study 39075732 — intervention group
Group type: EXPERIMENTAL
Intervention: SA IOL (IC-8 small aperture intraocular lens) targeted to -0.75 D
Number of subjects: 453
Study 39075732 — intervention group
Group type: EXPERIMENTAL
Intervention: SA IOL (IC-8 small aperture intraocular lens)
Number of subjects: 453
Study 39075732 — intervention group
Group type: EXPERIMENTAL
Intervention: SA IOL (IC-8 small aperture intraocular lens) with higher preoperative corneal astigmatism (1.0-1.5 D)
Number of subjects: 453
Study 39075732 — intervention group
Group type: COMPARATOR
Intervention: Monofocal/monofocal toric IOLs targeted to plano (control group)
Number of subjects: 453
Study 39075925 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 568
Study 39075931 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity (MHO)
Number of subjects: 84
Study 39075931 — intervention group
Group type: COMPARATOR
Intervention: Metabolically unhealthy obesity (MUO)
Number of subjects: 84
Study 39075931 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual metabolic syndrome (MS) markers
Number of subjects: 84
Study 39075946 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking + expressed breast milk
Number of subjects: 175
Study 39075946 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 175
Study 39076099 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilar (AryoTrust) administered every 3 weeks for nine cycles
Number of subjects: 597
Study 39076170 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying pathogenic/likely pathogenic (P/LP) variants
Number of subjects: 3071
Study 39076170 — intervention group
Group type: COMPARATOR
Intervention: Carrying variants of uncertain significance (VUS)
Number of subjects: 3071
Study 39076170 — intervention group
Group type: COMPARATOR
Intervention: Non-variant group
Number of subjects: 3071
Study 39076175 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraGraft©
Number of subjects: 15
Study 39076175 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 39076220 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score II (SS-II)
Number of subjects: 200
Study 39076220 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score 2020 (SS-2020)
Number of subjects: 200
Study 39076222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocovid capsules
Number of subjects: 250
Study 39076222 — intervention group
Group type: COMPARATOR
Intervention: Placebo containing palm superolein
Number of subjects: 250
Study 39076324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE) guidance
Number of subjects: 363
Study 39076324 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE) guidance
Number of subjects: 363
Study 39076386 — intervention group
Group type: EXPERIMENTAL
Intervention: High Cystatin C/Left Ventricular Ejection Fraction Ratio (CLR) group
Number of subjects: 14733
Study 39076427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen-to-albumin ratio (FAR)
Number of subjects: 66761
Study 39076438 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral Adiposity Tissue Index (VATI)
Number of subjects: 542
Study 39076438 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride-Glucose (TyG) index
Number of subjects: 542
Study 39076448 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity measured with accelerometer (Actigraph GTX3)
Number of subjects: 501
Study 39076448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time measured with accelerometer (Actigraph GTX3)
Number of subjects: 501
Study 39076483 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-cap fibroatheroma (TCFA), small luminal area, and large plaque burden (PB)
Number of subjects: 86
Study 39076483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TCFA and minimal lumen area (MLA)
Number of subjects: 86
Study 39076545 — intervention group
Group type: EXPERIMENTAL
Intervention: CALLY index quartile Q1 (lowest CALLY index)
Number of subjects: 3799
Study 39076545 — intervention group
Group type: EXPERIMENTAL
Intervention: CALLY index quartile Q2
Number of subjects: 3799
Study 39076545 — intervention group
Group type: EXPERIMENTAL
Intervention: CALLY index quartile Q3
Number of subjects: 3799
Study 39076545 — intervention group
Group type: EXPERIMENTAL
Intervention: CALLY index quartile Q4 (highest CALLY index)
Number of subjects: 3799
Study 39076545 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality (ACM)
Number of subjects: 3799
Study 39076545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac mortality (CM)
Number of subjects: 3799
Study 39076569 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) applied on the left upper limb twice daily, starting three days before DCB implantation.
Number of subjects: 653
Study 39076569 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 653
Study 39076569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 653
Study 39076593 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1905 (50, 100, 200, 400, and 600 mg)
Number of subjects: 0
Study 39076593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39076593 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1905
Number of subjects: 0
Study 39076624 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anesthesia (VA) - sevoflurane, isoflurane, or desflurane
Number of subjects: 1586
Study 39076624 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 1586
Study 39076658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,5-anhydroglucitol (1,5-AG) levels
Number of subjects: 270
Study 39076658 — intervention group
Group type: COMPARATOR
Intervention: Control group (MACCEs-free group)
Number of subjects: 270
Study 39076670 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on Lasso regression and multivariate logistic regression
Number of subjects: 338
Study 39076670 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with high risk of thromboembolism
Number of subjects: 338
Study 39076703 — intervention group
Group type: EXPERIMENTAL
Intervention: DynamX Bioadaptor
Number of subjects: 50
Study 39076700 — intervention group
Group type: EXPERIMENTAL
Intervention: Q4 group of HF patients
Number of subjects: 3114
Study 39076700 — intervention group
Group type: COMPARATOR
Intervention: Q1 and Q3 groups of HF patients
Number of subjects: 3114
Study 39076716 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) classifier
Number of subjects: 2108
Study 39076716 — intervention group
Group type: COMPARATOR
Intervention: Traditional APPROACH risk score
Number of subjects: 2108
Study 39076716 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning approaches
Number of subjects: 2108
Study 39076716 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 2108
Study 39076742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) mode
Number of subjects: 31
Study 39076742 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA) mode
Number of subjects: 31
Study 39076742 — intervention group
Group type: COMPARATOR
Intervention: Pressure-Regulated Volume Control (PRVC) mode
Number of subjects: 31
Study 39076748 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-derived index of microcirculatory resistance (angio-IMR) calculated based on computed flow and pressure dynamic principles.
Number of subjects: 118
Study 39076748 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for major adverse cardiovascular events (MACEs) including all-cause death, non-fatal myocardial infarction, target vessel revascularization (TVR), and stroke.
Number of subjects: 118
Study 39076751 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 50
Study 39076879 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT combined with strength training
Number of subjects: 44
Study 39076879 — intervention group
Group type: COMPARATOR
Intervention: HIIT
Number of subjects: 44
Study 39076944 — intervention group
Group type: EXPERIMENTAL
Intervention: CACS-weighted clinical likelihood (CACS-CL) model with cutoff of 5%
Number of subjects: 6689
Study 39076944 — intervention group
Group type: EXPERIMENTAL
Intervention: CACS-weighted clinical likelihood (CACS-CL) model with cutoff of 15%
Number of subjects: 6689
Study 39076951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 72
Study 39076951 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 72
Study 39076951 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 39077002 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory T cell (Treg)
Number of subjects: 182
Study 39077002 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak value of Creatine Kinase MB (pCKMB)
Number of subjects: 182
Study 39077002 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 182
Study 39077002 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular end-systolic diameter (LVESD)
Number of subjects: 182
Study 39077002 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated 4-marker panel (Treg, pCKMB, hsCRP, LVESD)
Number of subjects: 182
Study 39077002 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated 4-marker panel added to baseline risk model
Number of subjects: 182
Study 39077009 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit vessel size (small, medium, large)
Number of subjects: 404
Study 39077009 — intervention group
Group type: EXPERIMENTAL
Intervention: Different plaque phenotypes
Number of subjects: 404
Study 39077018 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly regulated diabetes
Number of subjects: 309
Study 39077018 — intervention group
Group type: COMPARATOR
Intervention: Well-regulated diabetes
Number of subjects: 309
Study 39077018 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetes
Number of subjects: 309
Study 39077018 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glycated hemoglobin (HbA1c) level
Number of subjects: 309
Study 39077018 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammatory mediators
Number of subjects: 309
Study 39077077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate hyperglycemia
Number of subjects: 14585
Study 39077077 — intervention group
Group type: COMPARATOR
Intervention: Normal glycemia
Number of subjects: 14585
Study 39077099 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus reducer (CSR) implantation
Number of subjects: 24
Study 39077099 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 24
Study 39077135 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-Fr Glidesheath Slender
Number of subjects: 504
Study 39077135 — intervention group
Group type: COMPARATOR
Intervention: Conventional 7-Fr Cordis sheath
Number of subjects: 504
Study 39077398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 13
Study 39077398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (HIIT + strength training)
Number of subjects: 13
Study 39077419 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloperoxidase (MPO) levels in HFpEF patients
Number of subjects: 55
Study 39077419 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of MPO in HFpEF patients
Number of subjects: 55
Study 39077419 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between oxidative stress and vascular stiffness
Number of subjects: 55
Study 39077421 — intervention group
Group type: COMPARATOR
Intervention: FFR-deferred vessels
Number of subjects: 1305
Study 39077421 — intervention group
Group type: COMPARATOR
Intervention: FFR-revascularized vessels
Number of subjects: 1305
Study 39077421 — intervention group
Group type: COMPARATOR
Intervention: Angio-revascularized vessels
Number of subjects: 1305
Study 39077421 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided vessels (both FFR-revascularized and FFR-deferred)
Number of subjects: 1305
Study 39077424 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing technology for transcatheter mitral valve interventions (TMVI)
Number of subjects: 0
Study 39077424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench test simulation and multi-material printing
Number of subjects: 0
Study 39077475 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased left ventricular end-diastolic diameter (LVEDD)
Number of subjects: 33147